KEYNOTE-811: First-line Pembrolizumab + Trastuzumab and Chemotherapy in HER2+ Metastatic Gastric or Gastroesophageal Junction Cancer

June 4-8, 2021; Online at
Interim analysis of the KEYNOTE-811 trial shows significantly higher response rate and more durable responses with pembrolizumab added to first-line trastuzumab and chemotherapy in gastric or gastroesophageal junction cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 412 KB
Released: June 17, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Enter the characteristics of your patients with pancreatic cancer into this online tool from Clinical Care Options (CCO) to receive expert treatment recommendations

Andrew H. Ko, MD
Program Director
Elena Gabriela Chiorean, MD Dan Laheru, MD person default Paul E. Oberstein, MD Michael J. Pishvaian, MD, PhD
Released: September 13, 2021

From Clinical Care Options (CCO), download a PDF featuring expert discussion of biomarkers in gastrointestinal cancers

John L. Marshall, MD Released: August 18, 2021

On-demand video from Clinical Care Options (CCO) with expert perspectives on using biomarkers to inform treatments for GI cancers

David H. Ilson, MD, PhD John L. Marshall, MD Eric Van Cutsem, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: August 16, 2021 Expired: August 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.